<DOC>
	<DOCNO>NCT00117117</DOCNO>
	<brief_summary>The purpose trial prospectively assess relationship change hemoglobin ( hgb ) change symptom burden associate anemia cancer patient receive chemotherapy support Aranesp® .</brief_summary>
	<brief_title>A Study Assess Symptom Burden Subjects With Nonmyeloid Malignancies Receiving Chemotherapy Aranesp®</brief_title>
	<detailed_description />
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Subjects nonmyeloid malignancy ( y ) Anemia ( hgb less equal 11.0 g/dL ) due cancer chemotherapy Subjects acute myelogenous leukemia ( AML ) , chronic myelogenous leukemia ( CML ) , myelodysplastic syndrome ( MDS ) Unstable cardiac disease anemia due cause</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Chemotherapy induce anemia</keyword>
	<keyword>Amgen</keyword>
	<keyword>Aranesp®</keyword>
	<keyword>darbepoetin alfa</keyword>
</DOC>